166 related articles for article (PubMed ID: 10521711)
1. A structural comparison of the total polar lipids from the human archaea Methanobrevibacter smithii and Methanosphaera stadtmanae and its relevance to the adjuvant activities of their liposomes.
Sprott GD; Brisson J; Dicaire CJ; Pelletier AK; Deschatelets LA; Krishnan L; Patel GB
Biochim Biophys Acta; 1999 Sep; 1440(2-3):275-88. PubMed ID: 10521711
[TBL] [Abstract][Full Text] [Related]
2. Safety of archaeosome adjuvants evaluated in a mouse model.
Patel GB; Omri A; Deschatelets L; Sprott GD
J Liposome Res; 2002 Nov; 12(4):353-72. PubMed ID: 12519630
[TBL] [Abstract][Full Text] [Related]
3. Archaeosomes varying in lipid composition differ in receptor-mediated endocytosis and differentially adjuvant immune responses to entrapped antigen.
Sprott GD; Sad S; Fleming LP; Dicaire CJ; Patel GB; Krishnan L
Archaea; 2003 Oct; 1(3):151-64. PubMed ID: 15803661
[TBL] [Abstract][Full Text] [Related]
4. In vitro evaluation of archaeosome vehicles for transdermal vaccine delivery.
Jia Y; McCluskie MJ; Zhang D; Monette R; Iqbal U; Moreno M; Sauvageau J; Williams D; Deschatelets L; Jakubek ZJ; Krishnan L
J Liposome Res; 2018 Dec; 28(4):305-314. PubMed ID: 28948854
[TBL] [Abstract][Full Text] [Related]
5. Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems.
Patel GB; Sprott GD
Crit Rev Biotechnol; 1999; 19(4):317-57. PubMed ID: 10723627
[TBL] [Abstract][Full Text] [Related]
6. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum.
Krishnan L; Dicaire CJ; Patel GB; Sprott GD
Infect Immun; 2000 Jan; 68(1):54-63. PubMed ID: 10603368
[TBL] [Abstract][Full Text] [Related]
7. Archaeosomes as novel antigen delivery systems.
Sprott GD; Tolson DL; Patel GB
FEMS Microbiol Lett; 1997 Sep; 154(1):17-22. PubMed ID: 9297816
[TBL] [Abstract][Full Text] [Related]
8. Safety and biodistribution of sulfated archaeal glycolipid archaeosomes as vaccine adjuvants.
Akache B; Stark FC; Iqbal U; Chen W; Jia Y; Krishnan L; McCluskie MJ
Hum Vaccin Immunother; 2018 Jul; 14(7):1746-1759. PubMed ID: 29336668
[TBL] [Abstract][Full Text] [Related]
9. Sulfated archaeal glycolipid archaeosomes as a safe and effective vaccine adjuvant for induction of cell-mediated immunity.
McCluskie MJ; Deschatelets L; Krishnan L
Hum Vaccin Immunother; 2017 Dec; 13(12):2772-2779. PubMed ID: 28537465
[TBL] [Abstract][Full Text] [Related]
10. Archaeosome immunostimulatory vaccine delivery system.
Patel GB; Chen W
Curr Drug Deliv; 2005 Oct; 2(4):407-21. PubMed ID: 16305444
[TBL] [Abstract][Full Text] [Related]
11. Methanobrevibacter smithii archaeosomes-entrapped mzNL4-3 virus-like particles induce specific T helper 1-oriented cellular and humoral responses against HIV-1.
Salmani AS; Aghasadeghi MR; Nategh R; Mokhtari-Azad T; Siadat SD
Curr HIV Res; 2013 Sep; 11(6):491-7. PubMed ID: 24329177
[TBL] [Abstract][Full Text] [Related]
12. Archaeosomes made of Halorubrum tebenquichense total polar lipids: a new source of adjuvancy.
Gonzalez RO; Higa LH; Cutrullis RA; Bilen M; Morelli I; Roncaglia DI; Corral RS; Morilla MJ; Petray PB; Romero EL
BMC Biotechnol; 2009 Aug; 9():71. PubMed ID: 19678953
[TBL] [Abstract][Full Text] [Related]
13. Archaeosome adjuvants: immunological capabilities and mechanism(s) of action.
Krishnan L; Sprott GD
Vaccine; 2008 Apr; 26(17):2043-55. PubMed ID: 18343538
[TBL] [Abstract][Full Text] [Related]
14. Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice.
Akache B; Stark FC; Jia Y; Deschatelets L; Dudani R; Harrison BA; Agbayani G; Williams D; Jamshidi MP; Krishnan L; McCluskie MJ
PLoS One; 2018; 13(12):e0208067. PubMed ID: 30513093
[TBL] [Abstract][Full Text] [Related]
15. Phosphatidylserine receptor-mediated recognition of archaeosome adjuvant promotes endocytosis and MHC class I cross-presentation of the entrapped antigen by phagosome-to-cytosol transport and classical processing.
Gurnani K; Kennedy J; Sad S; Sprott GD; Krishnan L
J Immunol; 2004 Jul; 173(1):566-78. PubMed ID: 15210818
[TBL] [Abstract][Full Text] [Related]
16. Archaeosomes as self-adjuvanting delivery systems for cancer vaccines.
Krishnan L; Dennis Sprott G;
J Drug Target; 2003; 11(8-10):515-24. PubMed ID: 15203920
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the immune responses induced by antigens in three different archaeosome-based vaccine formulations.
Jia Y; Akache B; Deschatelets L; Qian H; Dudani R; Harrison BA; Stark FC; Chandan V; Jamshidi MP; Krishnan L; McCluskie MJ
Int J Pharm; 2019 Apr; 561():187-196. PubMed ID: 30836154
[TBL] [Abstract][Full Text] [Related]
18. Short-term repeated-dose toxicity profile of archaeosomes administered to mice via intravenous and oral routes.
Omri A; Agnew BJ; Patel GB
Int J Toxicol; 2003; 22(1):9-23. PubMed ID: 12573945
[TBL] [Abstract][Full Text] [Related]
19. New generation of liposomes called archaeosomes based on natural or synthetic archaeal lipids as innovative formulations for drug delivery.
Benvegnu T; Lemiègre L; Cammas-Marion S
Recent Pat Drug Deliv Formul; 2009 Nov; 3(3):206-20. PubMed ID: 19534669
[TBL] [Abstract][Full Text] [Related]
20. Isopranoid- and dipalmitoyl-aminophospholipid adjuvants impact differently on longevity of CTL immune responses.
Dicaire CJ; Yu SH; Whitfield DM; Sprott GD
J Liposome Res; 2010 Dec; 20(4):304-14. PubMed ID: 20148707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
